Navigation Links
Tumor size and level of visceral pleura invasion can impact survival of NSCLC patients
Date:8/19/2009

AURORA, CoA study published in the August 2009 edition of the Journal of Thoracic Oncology found that non-small cell lung cancer (NSCLC) patients could be more accurately staged at diagnosis by taking into account the level of visceral pleura invasion (VPI). VPI is the extension of a tumor beyond the elastic layer of the visceral pleura.

Researchers from the National Cancer Center East in Kashiwa, Japan conducted a review of data from the Japanese Joint Committee for Lung Cancer Registration. After examining the records of 9,758 patients who underwent surgical resection in 1999, the patients were divided into nine groups based on tumor size and VPI.

The status of disease progression is determined through staging by measuring the presence of a localized tumor (T Status), presence of cancerous cells in the lymph nodes (N status) and metastasized tumors (M status). The TNM classification has several subgroups, or stages, that allow physicians to pinpoint the most accurate level of disease progression and develop a treatment plan. Using the International Association for the Study of Lung Cancer's staging model, Junji Yoshida, MD and his team concluded that a tumor 7cm or less with VPI should be upgraded to the next stage in T status.

"This research is extremely necessary in order to fine tune the lung cancer staging guidelines and be sure patients receive the most accurate staging and treatment," said Dr. Yoshida. "Accurate staging and course of treatment can impact the patient's prognosis tremendously."


'/>"/>

Contact: Bethany Fischer
bfischer@spectrumscience.com
202-955-6222
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
2. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
3. Study details regulation of vital tumor suppressor gene p53
4. Human C-reactive protein regulates myeloma tumor cell growth and survival
5. Customized virus kills brain tumor stem cells that drive lethal cancer
6. Study suggests brain tumors need treatment with multiple targeted drugs
7. Bright tumors, dim prospects
8. National Brain Tumor Foundation Unites with BrainLAB in Support of Patient Education
9. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
10. PET scans can accurately detect a breast tumors response to chemotherapy
11. DNA damage response confers a barrier for viral tumorigenesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: